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PharmacovigilanceBackground: Among all post-marketing medication error reports submitted to EudraVigilance, vaccines
are the most frequently reported medicinal products. This study aims to describe the characteristics of
vaccination errors submitted to Eudravigilance between 2001 and 2016.
Methods: EudraVigilance is a spontaneous reporting database for adverse events maintained by the
European Medicines Agency. We extracted Individual Case Safety Reports (ICSRs) submitted to
EudraVigilance between 1 January 2001 and 31 December 2016. Reports were included for analysis if
a vaccine was reported as interacting or suspect drug and at least one medication error term was listed
as an adverse reaction. ICSRs were stratified by age and gender, by year of reporting, region of origin,
reporter profession, seriousness of outcome, ATC, and type of error.
Results: In total, 7097 ICSRs were included in the study. We observed a yearly increase in the reporting of
vaccination errors, with the proportion to all vaccine ICSRs increasing from 0.4% to 4.0% between 2001
and 2016. The majority of reports was classified as serious (4248, 59.9%), but non-serious reports were
increasingly reported since 2012. The mean age of patients was 24.1 years. The most frequently reported
vaccines were influenza (13.5%), bacterial and viral combined (12.3%), and hepatitis vaccines (11.8%). A
total of 8167 medication error terms were reported. The most frequently reported terms were
‘‘Inappropriate schedule of drug administration” (27.2%), ‘‘Incorrect route of drug administration”
(12.5%) and ‘‘Drug administered to patient of inappropriate age” (10.0%). For infants and children, the
error ‘‘Drug administered to patient of inappropriate age” was reported more often than for all other
age categories.
Discussion: Vaccination errors are increasingly submitted to EudraVigilance. Errors related to the sched-
ule are the most common errors reported with vaccines. However, consequences of vaccination errors
appear to be relatively mild.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
In the EU, all adverse event reports are collected and shared in
EudraVigilance, a European wide pharmacovigilance database
[1,2]. Since July 2012 the EU pharmacovigilance legislation pro-
vides a legal framework to share data on medication errors, in
which medication errors are defined as ‘‘an unintended failure in
the drug treatment process that leads to, or has the potential to
lead to, harm to the patient” [1,3]. The definition of medication
errors in this legislation does not include ‘intended errors’ such
as off-label use, misuse and abuse [3]. In EudraVigilance, vaccines
are the most frequently reported medicinal group among medica-
tion errors cases in EU countries [4]. Several studies have reportedescrip-
2 C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxxdata on vaccination errors, although the majority of these origi-
nated from US reporting systems [5–14]. Although in some cases
vaccination errors may leave the patient unprotected against dis-
ease [15,16], vaccination errors do not necessarily cause injury.
Above mentioned studies in Vaccine Adverse Event Reporting Sys-
tem (VAERS) show that in general vaccination errors result in little
harm. Studies have shown that the reporting of vaccination errors
has increased in the past decade in the USA, which may be
explained by several reasons such as changes in reporting prac-
tices, the increasing number of vaccines in the national immuniza-
tion program, and increased awareness of the importance of
reporting medical errors [12,17].
Specific pharmacovigilance guidance has been developed for
vaccines as these have a specific position in the spectrum of medic-
inal products. In contrast to most regular medications, vaccines are
used to prevent rather than cure diseases and are used in relatively
healthy populations. As a result, fewer risks are tolerated with the
use of vaccines. Vaccines are often administered to large popula-
tions as part of public health programs. Moreover, specific storage
requirements apply to vaccines, and vaccination schedules may be
complex and difficult to adhere to [18]. Errors may occur at any
stage of the treatment process and consequences of errors associ-
ated with vaccines may be different from other medications.
The role of spontaneous reporting systems in the context of
medication errors has been described for medications in general,
but limited knowledge is available on vaccination errors submitted
to EudraVigilance. In the current study, we aim to describe vacci-
nation errors in EudraVigilance, to gain insight into the types of
errors and to identify potential areas where preventive measures
may be beneficial.
2. Methods
2.1. Study design
A descriptive case series study was performed in EudraVigilance
on vaccination errors reported by a healthcare professional (HCP)
or non-HCP to an EU national competent authority (NCA) or mar-
keting application holder (MAH) in the period of 1 January 2001
through 31 December 2016. We retrieved all reports and as refer-
ence date for all analyses we used the date when an NCA or MAH
received the initial report. If multiple versions of the same report
were identified, only the latest version was used for further analy-
sis. For the analysis, all Individual Case Safety Reports (ICSRs)
reporting a medication error term and at least one vaccine as a sus-
pect medication, were downloaded from the EudraVigilance Post
Authorization Module. Therefore, only post-marketing ICSRs were
included. All ICSRs were extracted on 11 September 2017.
2.2. ICSR extraction
Vaccines were identified by searching for active substances of
vaccines using search terms such as human papilloma, herpes,
influenza, et cetera. Subsequently, all drugs identified in the
selected reports were classified by Anatomical Therapeutic Classi-
fication (ATC) code. Drugs with an ATC code not starting with J07
were excluded from the analysis. All adverse drug reactions and
clinical terms (e.g. diagnostics) reported in the ICSRs are coded
by the Medical Dictionary for Regulatory Activities (MedDRA) ter-
minology1. All ICSRs submitted within the study period were
extracted using the narrow Standardised MedDRA query (SMQN)1 MedDRA is the international medicinal terminology developed under the
auspices of the International Council on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use (ICH). MedDRA trademark is
owned by IFPMA on behalf of ICH.
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tion of MedDRA preferred terms (PTs) to identify medication error
cases (e.g. administration error or product administered to wrong
patient). All PT’s listed in the SMQN were categorized into 10 error
groups based on the types of errors: Accidental exposure, Adminis-
tration errors, Contraindication/Warning, Dispensing/selection/pre
scription error, General error, Information error, Storage error or
quality-related issue, Vaccination incomplete, Wrong dose, Wrong
patient/drug/age (Appendix A). Reported cases in EudraVigilance
are classified as serious when categorized in at least one of the fol-
lowing subcategories: death, life-threatening, hospitalization, dis-
abling, congenital anomaly or other nature according to the ICH
definitions [19,20].2.3. Analysis
The reports extracted from EudraVigilance were classified by
age and gender, by year and month of reporting, region of origin
of the report (EU or non-EU), reporter profession (healthcare pro-
fessional or non-healthcare professional), seriousness of reported
outcome, ATC level 4, and PT. All countries associated with the
European Medicines Agency (i.e. EU countries plus Iceland, Liecht-
enstein, and Norway) were classified as EU. Patients were catego-
rized in age groups as follows: infants 0 < 2 years, children
2 < 12 years, adolescents 12 < 18 years, adults 18 < 65 years,
elderly 65 < 75 years, very elderly  75 years. Where applicable a
two-sided binomial test was performed to compare proportions,
with the null-hypothesis assuming that there is no difference
between the proportions of the categories tested. The aim of such
testing was to highlight differences in reporting of vaccination
errors that may need further evaluation, rather than to confirm dif-
ferences in the occurrence of vaccination errors. Data handling and
analysis were performed in SAS software version 9.3 (SAS Institute
Inc., USA). Missing data were considered as ‘not reported’ and
formed an extra outcome category.3. Results
Between 1 January 2001 and 31 December 2016, there were
233,285 vaccine reports of which 7097 (3.0%) reported a vaccina-
tion error. The number of vaccination error reports received per
year increased from 5 in 2001 to 1007 in 2016 (Fig. 1). Simultane-
ously, the proportion of vaccination error reports among all vac-
cine reports increased from 0.4% to 4.0%. However, among all
medication error reports in EudraVigilance, the proportion of vac-
cination errors decreased during the study period and reached 4.1%
in 2016 (Fig. 1). Among all medication errors reported in EudraVig-
ilance, 5.5% concerned vaccination errors, ranging from 1.5 to 8.9%
per year. In 2012 the number of reports was almost twice as high
as in 2011, mainly due to an increase in non-serious reports. After
2012 the proportion of non-serious reports remained high. The
majority of cases was received from HCPs (89.9%). In each study
year the proportion reported by HCPs was at least 80.0%. The
majority of reports received in the study period was spontaneous
(95.7%; Table 1). Other report types were reports from study
(3.4%; e.g. reports from compassionate use programs, or
pharmaco-epidemiological studies), other (0.3%; e.g. when it is
not clear from a literature study whether it arose from sponta-
neous observation or from a study) and in 0.6% of the reports infor-
mation on the source was not available. The majority of cases
originated from the EU (4269; 60.2%; table 1).
Of all reported vaccination errors more than half (59.9%) were
serious (table 1) meaning at least one of the following categories
was applicable: (1) death, (2) life-threatening, (3) hospitalization,
(4) disability, (5) congenital anomaly, or (6) other. The categorytion errors in the European regulatory database EudraVigilance: A descrip-
Fig. 1. Number and percentage of vaccination error ICSRs submitted to EudraVigilance per year presented by seriousness of the report. The bars represent the absolute
number of serious (blue) and non-serious (green) vaccination errors. The lines represent the percentage of vaccination error cases to the total number of medication error
ICSRs submitted in EudraVigilance per year: percentage serious vaccination errors of all serious medication errors (red), percentage non-serious vaccination errors of all non-
serious medication errors (orange), percentage vaccination errors of all medication errors (yellow). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Table 1
Characteristics of vaccination error ICSRs submitted to EudraVigilance between 2001 and 2016.
Variable Level Total (7097) <18 years (3023) 18 years (2270)
N (%) N (%) N (%)
Gender Female 3913 (55.1) 1468 (48.6) 1875 (67.7)
Male 2493 (35.1) 1352 (44.7) 817 (29.5)
Not Specified 691 (9.7) 203 (6.7) 78 (2.8)
Reporter Profession Healthcare Professional 6380 (89.9) 2787 (92.2) 2422 (87.4)
Non-Healthcare Professional 711 (10.0) 234 (7.7) 346 (12.5)
Not Specified 6 (0.1) 2 (0.1) 2 (0.1)
Outcome Serious Any type 4248 (59.9) 2029 (67.1) 1721 (62.1)
Death 187 (2.6) 83 (2.7) 54 (1.9)
Life threatening 216 (3.0) 94 (3.1) 100 (3.6)
Hospitalization 1554 (21.9) 858 (28.4) 536 (19.4)
Disabling 414 (5.8) 110 (3.6) 269 (9.7)
Congenital anomaly 13 (0.2) 5 (0.2) 5 (0.2)
Other 2772 (39.1) 1272 (42.1) 1149 (41.5)
Geographic Location EU 4269 (60.2) 1829 (60.5) 1511 (54.5)
Non-EU 2828 (39.8) 1194 (39.5) 1259 (45.5)
Report Type Spontaneous 6794 (95.7) 2978 (98.5) 2618 (94.5)
Report from study 239 (3.4) 27 (0.9) 120 (4.3)
Other 21 (0.3) 4 (0.1) 4 (0.1)
Not available 43 (0.6) 14 (0.5) 28 (1.0)
Age of Patient Mean 24.1 years 4.68 45.20
Median 16 years 1 43
Minimum 0 years 0 18
Maximum 99 years 17 99
Standard deviation 24.49 years 5.78 19.00
Missing 1304 0 0
C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxx 3‘other’ was reported in two-thirds (65.3%) of all serious cases, fol-
lowed by ‘hospitalisation’ (36.6%). Death was reported mostly in
the very elderly (75 years) compared to the other age categories
(13.4% vs 1.7–5.1%; Fig. 2). Disabling outcome was reported more
frequently in patients of 12 years and older compared to in infants
and children (14.4–18.7% versus 3.4–3.8%). Fig. 4 shows the differ-Please cite this article in press as: Hoeve CE et al. Spontaneous reports of vaccina
tive study. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.11.003ent proportions of vaccination errors per vaccine for serious and
non-serious cases. Fig. 5 shows the distribution of seriousness cat-
egories per vaccine.
Reports concerned females significantly more often than males
(p < 0.001). More than half of the cases were reported in women
(55.1%) and males were mentioned in approximately one third oftion errors in the European regulatory database EudraVigilance: A descrip-
Fig. 2. Percentage of serious categories applicable for vaccination error ICSRs by age category. Percentages are calculated for each age category as the number of ICSRs in the
specific seriousness category to the total of serious ICSRs.
Fig. 3. Number of vaccination error ICSRs received by Age and Gender. The lines represent the number of ICSRs per age and per gender. The bars represent the approximate
number of administrations given for each age. The German national immunization schedule was used as a reference for the number of administrations as the majority of
ICSRs originated from Germany (Vaccination Schedule Germany. German Standing Committee on Vaccination (STIKO) recommendations, 2017/18. From https://www.rki.de/
DE/Content/Infekt/Impfen/Materialien/Downloads-Impfkalender/Impfkalender_Englisch.pdf?__blob=publicationFile. Accessed on 13 July 2018).
4 C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxxthe cases (35.1%). In the remaining cases, gender was unknown
(9.7%). In total, the ratio of female to male reports was 1.6. The
mean age of patients (if provided) was 24.06 years and the median
16. In 18.4% of the cases age was not reported (table 1). Approxi-
mately a quarter of all vaccination errors occurred in infants
(26.2%). The age distribution was similar in males and females
(Fig. 3). However, among adolescents more reports occurred in
females. This could be explained by reporting of cases related to
papilloma virus vaccines, for which 97.3% of the errors occurred
in females. After excluding cases reporting a papilloma virus vac-
cine the ratio of female to male was still significant (p < 0.001)
although smaller (1.2).Please cite this article in press as: Hoeve CE et al. Spontaneous reports of vaccina
tive study. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.11.003The majority of adverse events reported after vaccination errors
were mild in nature and well known to be associated with vaccine
use (e.g. pyrexia, headache and pain in extremity). In table 2 the
most frequently reported adverse events are presented for serious
and non-serious reports.
Most often reported vaccines were influenza vaccines (957;
13.5%), bacterial and viral vaccines combined (872; 12.3%), and hep-
atitis vaccines (835; 11.8%). The most frequent bacterial and viral
combination vaccines reported were the hexavalent diphtheria-
haemophilus influenza B (HiB)-pertussis-poliomyelitis-tetanus-he
patitis B combination (40.8%), followed by diphtheria-pertussis-po
liomyelitis-tetanus (27.1%) and diphtheria-HiB-pertussis-poliomyetion errors in the European regulatory database EudraVigilance: A descrip-
Fig. 4. Number of vaccination error ICSRs by ATC level 5. Data is divided into non-serious ICSRs (green) and serious ICSRs (blue). (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Number of vaccination error ICSRs by vaccine, age, error category and seriousness category. Each number in the figure corresponds to the absolute number of ICSRs
reported for the indicated vaccine and age, error or seriousness category. The vaccines reported most frequently are presented at the bottom of the chart.
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Table 2
Adverse events reported in vaccination error Individual Case Safety Reports (ICSRs). Preferred terms included in the narrow Standardised MedDRA Query or the preferred term ‘No
adverse event’ are excluded from this table. Of note: vaccination failure is a term which refers to the failure of the vaccine itself, rather than to an error in the treatment process.
ADRs overall Adverse events in serious ICSRs Adverse events in non-serious ICSRs
Adverse event N (%) Adverse event N (%) Adverse event N (%)
1 Pyrexia 883 (3.9) Pyrexia 713 (3.6) Pyrexia 170 (6.1)
2 Vaccination failure 383 (1.7) Vaccination failure 317 (1.6) Syringe issue 93 (3.3)
3 Headache 312 (1.4) Headache 258 (1.3) Pain in extremity 74 (2.6)
4 Pain in extremity 293 (1.3) Vomiting 250 (1.3) Underdose 69 (2.5)
5 Vomiting 284 (1.3) Exposure during pregnancy 227 (1.2) Vaccination failure 66 (2.4)
6 Exposure during pregnancy 252 (1.1) Pain in extremity 219 (1.1) Erythema 59 (2.1)
7 Fatigue 235 (1.0) Pain 204 (1.0) Vaccination site pain 59 (2.1)
8 Pain 233 (1.0) Nausea 202 (1.0) Headache 54 (1.9)
9 Erythema 230 (1.0) Fatigue 200 (1.0) Injection site erythema 49 (1.8)
10 Nausea 227 (1.0) Diarrhoea 176 (0.9) Overdose 48 (1.7)
11 Malaise 217 (1.0) Malaise 176 (0.9) Vaccination site erythema 44 (1.6)
12 Diarrhoea 200 (0.9) Erythema 171 (0.9) Off label use 43 (1.5)
13 Asthenia 183 (0.8) Seizure 169 (0.9) Malaise 41 (1.5)
14 Dyspnoea 179 (0.8) Dyspnoea 167 (0.8) Vaccination site swelling 41 (1.5)
15 Arthralgia 174 (0.8) Dizziness 158 (0.8) Injection site pain 39 (1.4)
16 Injection site pain 173 (0.8) Asthenia 156 (0.8) Injection site swelling 36 (1.3)
17 Dizziness 171 (0.8) Arthralgia 150 (0.8) Fatigue 35 (1.3)
18 Injection site erythema 171 (0.8) Rash 143 (0.7) Vomiting 34 (1.2)
19 Seizure 169 (0.8) Cough 137 (0.7) Pain 29 (1.0)
20 Rash 160 (0.7) Varicella 137 (0.7) Influenza like illness 28 (1.0)
6 C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxxlitis-tetanus (16.5%). In infants (0 < 2 years) and children
(2 < 12 years) errors in products with bacterial and viral vaccines
combinedwere reportedmost frequently: 17.8% in infants (ofwhich
60.1% hexavalent vaccine [J07CA09] and 20.7% pentavalent vaccine
[J07CA06]) and16.2% in children (ofwhich37.1%hexavalent vaccine
[J07CA09] and 30.9% a combination vaccine of diphtheria-pertussis-
poliomyelitis-tetanus [J07CA02]). In adolescents (12 < 18 years)
errors with papilloma virus vaccines were reported most often
(47.1%),whereas in adults thesewere errorswithhepatitis virus vac-
cines (15.2%), and in the elderly and very elderly errors with pneu-
mococcal virus vaccines (27.7% and 28.3%) (Fig. 5).
Within the 7097 cases, a total of 8122 MedDRA PT’s associated
with medication errors were reported, which were categorized into
10 error groups as per Appendix A. The most frequently reported
error group related to non-compliance to the vaccination schedule
(36.1%). Most of these cases related to adult patients (48.8%). Sec-
ondary to this error category were administration errors (22.1%)Fig. 6. Number of vaccination error ICSRs by error category and age category. Each nu
indicated error and age category.
Please cite this article in press as: Hoeve CE et al. Spontaneous reports of vaccina
tive study. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.11.003and errors relating to a wrong (age of) patient or drug (14.6%)
(Fig. 6). The last category was particularly frequent in pediatric
patients: 41.9% of these cases were reported in infants (0 < 2 years)
and 64.3% in infants and children (<12 years) combined (Fig. 6).
Only in infant cases administration errors were reported more fre-
quently than non-compliance issues (29.8%).
The most frequently reported vaccine-error combination was
encephalitis vaccine with an error related to non-compliance of
the vaccination schedule (5.6%) (Fig. 5). Other vaccines frequently
reported with schedule related errors were papilloma (5.3%) and
hepatitis vaccines (5.1%). However, when considering age cate-
gories, the highest fraction reported was for schedule errors with
hepatitis B vaccines in adults. Vaccines frequently reported with
administration errors were influenza, tuberculosis and pneumo-
coccal vaccines. Errors with a wrong age of patient, wrong patient
or wrong drug were mostly reported with influenza, bacterial and
viral combined, and measles vaccines.mber in the figure corresponds to the absolute number of ICSRs reported for the
tion errors in the European regulatory database EudraVigilance: A descrip-
C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxx 74. Discussion
In our study we present data on vaccination errors identified in
the EudraVigilance database. Although several studies have
described vaccination errors based on spontaneously reported
adverse event reports in the VAERS database [5–12], to our knowl-
edge studies on spontaneous reports of vaccination errors in
EudraVigilance are not available.
We observed several key findings:
First, since 2001 we observed a continuous increase of vaccina-
tion errors reported to EudraVigilance. This is in line with the US
VAERS data for which an increase in vaccination errors was
observed during the past decade [12]. It is also in line with the
overall observed increase of medication errors in EudraVigilance
[4], which could be explained by better infrastructure for sponta-
neous reporting of adverse events and shifting cultures in health-
care organizations.
Second, there is a change in the ratio of serious and non-serious
reports. The vast majority (>75%) of error reports was categorized
as serious until 2011, but since 2012 an increase in non-serious
reports was observed. The majority of non-serious reports in the
EudraVigilance database originated from Germany, and 80% of
the German reports was non-serious. The increase in non-serious
reports may be driven by the change in the EU pharmacovigilance
legislation which was adopted in 2010 (and implemented in 2012).
One of the major changes was the obligation for MAHs and NCAs to
report not only serious, but also non-serious adverse event reports
to EudraVigilance [2]. For the transitional period, however, EU
countries could take different approaches for exchange of non-
serious adverse events that occurred in the EU. Germany had, as
the only member state, specific obligations in place for non-
serious reports related to vaccines [21]. This may explain the dif-
ference in the serious vs non-serious ratio between Germany and
other countries in the EU. With the launch of a new EudraVigilance
system in November 2017, the transitional period has ended. Non-
serious reports from all EU countries are now collected in
EudraVigilance and as a result it is expected that the number of
adverse event reports, including vaccination error reports, will
increase drastically. For most vaccines, the proportion of serious
cases was higher than non-serious cases. Especially tuberculosis
vaccines and HiB vaccines concerned almost solely serious cases
(both 97.3%).
Third, we also observed a substantial number of fatal cases fol-
lowing vaccination errors. From the current observations, no con-
clusions can be drawn with regards to causality between the
reported errors and fatal outcomes. It may be hypothesized that
the relatively small number of fatal outcomes, compared to the
large exposure, is due to causes unrelated to vaccines in patients
who had only coincidentally received recent immunizations. Addi-
tionally, a serious outcome may be more likely to be reported
when occurring immediately following immunization even though
not caused by it (Silvers 2001). Vaccination errors have the poten-
tial to result in very serious outcomes. For example administration
of contra-indicated vaccines may result in serious adverse events
and have been reported in association with fatal outcomes (Costa
2016). On the other hand, administration of the wrong vaccine,
incomplete vaccination or storage errors (with potential to affect
the effectiveness of the vaccine) can result in a failure to protect
the patient against the intended disease. Failure of immunization
may lead to serious disease courses for unprotected patients and
potentially to serious outcomes. Although our results show that
in general the reported adverse events are mild and also known
to be associated with appropriate use of vaccines, serious out-
comes or lack of protection of patients do occur in rare cases. It
is therefore important to investigate the causality of these seriousPlease cite this article in press as: Hoeve CE et al. Spontaneous reports of vaccina
tive study. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.11.003cases and to identify root-causes of errors, so measures can be
taken to prevent future harm. Therefore, the cases of fatal out-
comes after errors warrant further research. A manuscript evaluat-
ing these cases in depth is in preparation.
Fourth, gender and age are strong determinants: we observed
that a large number of vaccination errors were reported in the
young pediatric population (<12 years), while for those 12 years
and older the number of reported vaccination errors was relatively
low, which may be explained by the fact that vaccination schedules
often target young children [17,22]. The low observed number of
vaccination error reports in the elderly may be explained by the
fact that vaccines for the elderly do not require immunization
schedules, and usually only one vaccine is administered at a time
(e.g. influenza or pneumococcal vaccines) [22]. The gender ratio
(excluding papilloma virus vaccines) observed in our data was in
line with the gender ratio described for overall adverse event
reports in EudraVigilance [23]. The inclusion of human papilloma
virus vaccines resulted in a strong increase in the female to male
ratio. Women are known to experience/report more adverse events
thus the pattern is in line with expectations [24,25].
Since exposure data is not available in EudraVigilance, it is dif-
ficult to draw conclusions with regards to the proportion of errors
per vaccine. We providedmultiple vaccine specific results as it may
be useful to focus on vaccine-error combinations, as these may
indicate a recurring problem. It was noted that errors related to
vaccines which are administered at all ages (such as influenza vac-
cines) were reported most frequently, whereas errors related to
vaccines predominantly administered in infants (such as hexava-
lent vaccines) were reported more in the youngest age category.
When we focus on the type of errors, inappropriate schedule of
drug administration was reported most frequently in almost all
age categories, which is line with the publication by Hibbs et al
on vaccines [12]. Schedule errors with encephalitis, human papil-
loma virus, and hepatitis vaccines were the most frequently
reported error-vaccine combinations. A recent study performed
among German paediatric practices showed that indeed adherence
to the encephalitis immunization schedule was low, as only 28% of
patients who received an initial immunization returned for the
second and third injections [26]. Likewise, for HPV vaccination
non-completion of the schedule is high [27]. The most frequently
reported error-vaccine combination by age category was schedule
errors with hepatitis B vaccines in adults. A recent study reported
that hepatitis B coverage in the US was suboptimal [28]. The most
common reason for non-completion of the two-dose schedule was
lack of immunization opportunities [28]. Other reasons for non-
completion of an immunization schedule may relate to costs or
immunization hesitancy [28]. Several methods have been sug-
gested to reduce schedule errors, such as providing patients with
personalized calendars [29], stimulating patients to maintain their
immunization history [30] or alerting patients via SMS technology
[31]. For infants, administration errors were reported most fre-
quently, of which the majority were related to incorrect route or
inappropriate site of drug administration. Frequently reported
administration errors were reported due to intramuscular adminis-
tration of Priorix tetra instead of subcutaneous administration
(24%), subcutaneous administration of Prevenar instead of intra-
muscular administration (13%) and injection of rotavirus vaccines
instead of oral administration (13%). Most commonly reported
adverse events in these cases were lymphadenitis (41.8% of cases).
5. Limitations
Our study has several limitations. First, EudraVigilance is pri-
marily designed for the collection of spontaneous adverse event
reports. While underreporting is a well-known limitation fortion errors in the European regulatory database EudraVigilance: A descrip-
8 C.E. Hoeve et al. / Vaccine xxx (2018) xxx–xxxspontaneous reporting databases, this may be even more relevant
for medication errors as fear of possible consequences or absence
of a culture to share and acknowledge errors are known factors
that inhibit medication error reporting. With the new legislation
(implemented in 2012) the definition of adverse drug reactions
has been extended to include medication errors. As a consequence,
medication errors that result in harm should also be submitted to
EudraVigilance. Due to the nature of spontaneous reports, the
numbers in this review should be interpreted with care and serve
first of all as a way to identify areas with risk for errors, rather than
to quantify these risks. Additionally, in this review, no causality
assessment is performed with regards to adverse events or out-
comes. All vaccination error cases received by MAHs are discussed
routinely in periodic safety update reports to regulatory authori-
ties. All EudraVigilance reports are monitored continuously for
new adverse reactions or unexpected outcomes and are in addi-
tion, reviewed and discussed in the PSURs. Second, when multiple
medications are listed in one report as suspect (or interacting), it is
not always clear which of the reported medications was actually
involved in the error. As 73% of reports listed only one suspect or
interacting medication, it can be assumed that for the majority of
reports the vaccine reported was in fact involved in the error. With
the implementation of the new ICH-E2B(R3) reporting format in
the EudraVigilance system in November 2017, there is the possibil-
ity to ‘flag’ the medication that is related to a medication error [19].
This will support and improve analysis of medication error cases in
EudraVigilance. Third, extraction of the dataset was based on the
MedDRA SMQN for medication errors. However, more relevant
cases may be available in EudraVigilance, as cases where the repor-
ter was not aware of an error are not likely to be coded with one of
these terms. Additional search strategies could potentially provide
additional cases of vaccination errors. For example, using lot/batch
IDs or the product name in combination with the reported patient
age could help in identifying cases where a product has been
administered to an incorrect age group [32].6. Conclusion
The number of vaccination errors submitted to EudraVigilance
is increasing. It is expected that this number will further increase
in the future, especially with the fully functional database
launched in November 2017, after which also non-serious cases
from the EU should be submitted to EudraVigilance. Vaccination
errors vary by age, and the most frequent errors involve inappro-
priate schedules. As the distribution of error categories followed
a similar pattern for all vaccines, it seems that risk minimization
does not necessarily need to focus on the vaccine, but rather on
the error. For example, clear schedules and reminders for patients
may reduce schedule issues, whereas clearer instructions may
reduce administration errors, regardless of the vaccine involved.
In this study, we analyzed vaccines separately from other medica-
tions which may optimize identification of risk factors for vaccina-
tion errors that could be lost when analyzed in the large bulk of
general medication error reports.Funding
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